JP2005508371A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005508371A5 JP2005508371A5 JP2003541826A JP2003541826A JP2005508371A5 JP 2005508371 A5 JP2005508371 A5 JP 2005508371A5 JP 2003541826 A JP2003541826 A JP 2003541826A JP 2003541826 A JP2003541826 A JP 2003541826A JP 2005508371 A5 JP2005508371 A5 JP 2005508371A5
- Authority
- JP
- Japan
- Prior art keywords
- food supplement
- composition
- amount
- pharmaceutical
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000015872 dietary supplement Nutrition 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 6
- 239000011651 chromium Substances 0.000 claims 6
- 229910052804 chromium Inorganic materials 0.000 claims 6
- 229960003512 nicotinic acid Drugs 0.000 claims 6
- 235000001968 nicotinic acid Nutrition 0.000 claims 6
- 239000011664 nicotinic acid Substances 0.000 claims 6
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N (+)-Erythro-hydroxycitric acid Natural products OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 claims 4
- ZMJBYMUCKBYSCP-AWFVSMACSA-N (1s,2r)-1,2-dihydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)[C@@H](O)[C@@](O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-AWFVSMACSA-N 0.000 claims 4
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 claims 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims 4
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 4
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 claims 4
- 235000010081 allicin Nutrition 0.000 claims 4
- 229930014669 anthocyanidin Natural products 0.000 claims 4
- 235000008758 anthocyanidins Nutrition 0.000 claims 4
- 229930183009 gymnemic acid Natural products 0.000 claims 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 4
- 229930182490 saponin Natural products 0.000 claims 4
- 150000007949 saponins Chemical class 0.000 claims 4
- 239000011669 selenium Substances 0.000 claims 4
- 229910052711 selenium Inorganic materials 0.000 claims 4
- 235000018991 trans-resveratrol Nutrition 0.000 claims 4
- 239000011701 zinc Substances 0.000 claims 4
- 229910052725 zinc Inorganic materials 0.000 claims 4
- 150000001452 anthocyanidin derivatives Chemical class 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 2
- 235000017709 saponins Nutrition 0.000 claims 2
- 235000011649 selenium Nutrition 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32789601P | 2001-10-05 | 2001-10-05 | |
| PCT/US2002/031987 WO2003039535A1 (en) | 2001-10-05 | 2002-10-07 | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005508371A JP2005508371A (ja) | 2005-03-31 |
| JP2005508371A5 true JP2005508371A5 (enExample) | 2005-12-22 |
Family
ID=23278548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003541826A Pending JP2005508371A (ja) | 2001-10-05 | 2002-10-07 | インスリン抵抗性症候群の症状を予防するかまたは低下させるための方法と組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US7119110B2 (enExample) |
| EP (1) | EP1438038A4 (enExample) |
| JP (1) | JP2005508371A (enExample) |
| AU (1) | AU2002351456B2 (enExample) |
| CA (1) | CA2462158A1 (enExample) |
| IL (1) | IL161186A0 (enExample) |
| MX (1) | MXPA04003233A (enExample) |
| WO (1) | WO2003039535A1 (enExample) |
| ZA (1) | ZA200402688B (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1011660A1 (en) | 1997-07-14 | 2000-06-28 | Inter-Health Nutraceuticals Incorporated | Hydroxycitric acid compositions, pharmaceutical and dietary supplements and food products made therefrom, and methods for their use in reducing body weight |
| US20040157929A1 (en) * | 2002-04-01 | 2004-08-12 | Ohia Sunny E. | Method for increasing serotonin levels in a person by administration of a composition incorporating(-)hydroxycitric acid, and related compositions thereof |
| US7119110B2 (en) | 2001-10-05 | 2006-10-10 | Interhealth Nutraceuticals Incorporated | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
| US20030119913A1 (en) * | 2001-12-20 | 2003-06-26 | Ohia Sunny E. | Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof |
| WO2003074027A2 (en) * | 2002-03-01 | 2003-09-12 | Novagali Pharma Sa | Self emulsifying drug delivery systems for poorly soluble drugs |
| US7977049B2 (en) * | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| TW200427447A (en) * | 2003-03-21 | 2004-12-16 | Interhealth Nutraceuticals Inc | Method and composition for decreasing ghrelin levels |
| AU2004253579B2 (en) * | 2003-07-01 | 2010-12-23 | Biomol International L.P. | Sirt1 modulators for manipulating cells/organism lifespan/stress response |
| US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| US20050171027A1 (en) | 2003-12-29 | 2005-08-04 | President And Fellows Of Harvard College | Compositions for treating or preventing obesity and insulin resistance disorders |
| PT1577320E (pt) | 2004-03-19 | 2012-10-30 | Pasteur Institut | Péptidos derivados da proteína bplp humana, polinucleótidos que codificam para os referidos péptidos e anticorpos dirigidos contra os referidos péptidos |
| US20050215644A1 (en) * | 2004-03-19 | 2005-09-29 | Interhealth Nutraceuticals, Inc. | Methods for increasing neurotransmitter levels using hydroxycitric acid |
| EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
| JP2008503479A (ja) * | 2004-06-16 | 2008-02-07 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Ｂａｘ媒介性アポトーシスを調節する方法及び組成物 |
| EP1762234A4 (en) * | 2004-06-28 | 2010-05-05 | Kao Corp | AMPK AKTIVATOR |
| JP2006273834A (ja) * | 2004-06-28 | 2006-10-12 | Kao Corp | Ａｍｐｋ活性化剤 |
| WO2006004722A2 (en) * | 2004-06-30 | 2006-01-12 | Biomol Research Laboratories, Inc. | Compositions and methods for selectively activating human sirtuins |
| US20060029642A1 (en) * | 2004-08-03 | 2006-02-09 | Dusan Miljkovic | Methods and compositions for improved chromium complexes |
| WO2006138418A2 (en) | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
| US20070149466A1 (en) * | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| EP1942919B1 (en) * | 2005-09-28 | 2014-08-27 | The Regents of The University of California | Method for lowering blood pressure in pre-hypertensive individuals and/or individuals with metabolic syndrome |
| US7912716B2 (en) * | 2005-10-06 | 2011-03-22 | Sony Online Entertainment Llc | Generating words and names using N-grams of phonemes |
| JP2007126390A (ja) * | 2005-11-02 | 2007-05-24 | Mercian Corp | 血糖値低下剤 |
| WO2007143002A2 (en) * | 2006-05-31 | 2007-12-13 | Interhealth Nutraceuticals, Inc. | Nutraceutical treatments for diabetic and non-diabetic wound healing |
| US20100062087A1 (en) * | 2006-06-02 | 2010-03-11 | Interhealth Nutraceuticals, Inc. | Nutraceutical Treatments for Diabetic and Non-Diabetic Wound Healing |
| JP5045879B2 (ja) * | 2006-06-07 | 2012-10-10 | 株式会社龍泉堂 | インスリン抵抗性の改善効果、体重増加の抑制効果、及び脂肪肝の予防及び改善効果を有する混合物 |
| TW201002332A (en) * | 2008-07-07 | 2010-01-16 | Univ Nat Chunghsing | Composition for preventing and controlling fatty liver disease |
| CN102264228A (zh) | 2008-10-22 | 2011-11-30 | 默沙东公司 | 用于抗糖尿病药的新的环状苯并咪唑衍生物 |
| AU2009309037A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US20100323031A1 (en) * | 2009-06-22 | 2010-12-23 | Glykon Technologies Group, Llc | Synergistic combination to enhance blood glucose and insulin metabolism |
| EP2538784B1 (en) | 2010-02-25 | 2015-09-09 | Merck Sharp & Dohme Corp. | Benzimidazole derivatives useful anti-diabetic agents |
| WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| EA025380B1 (ru) | 2011-02-25 | 2016-12-30 | Мерк Шарп Энд Домэ Корп. | Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов |
| US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| BR112015019836A2 (pt) | 2013-02-22 | 2017-07-18 | Merck Sharp & Dohme | composto, composição farmacêutica, e, uso de um composto |
| US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| SG11201609600UA (en) * | 2014-06-12 | 2016-12-29 | Four LLC | Sweet taste receptor antagonist compositions |
| CN106491641A (zh) * | 2016-10-28 | 2017-03-15 | 乌林奇 | 一种靶向防治脑血栓的药物活性组合物及应用 |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| IT201700032960A1 (it) * | 2017-03-24 | 2018-09-24 | Akademy Pharma S R L | Composto nutraceutico per il trattamento dell’eccesso di peso e della moderata ipercolesterolemia e disglicemia |
| EP4156970A4 (en) * | 2020-06-02 | 2024-06-19 | Glykon Technologies Group, LLC. | Reducing triglyceride levels and cortisol levels with pharmaceutical preparations |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3764692A (en) | 1970-09-30 | 1973-10-09 | Hoffmann La Roche | Method of treating obesity |
| US4954492A (en) * | 1983-07-08 | 1990-09-04 | The William Seroy Group | Synthetic GTF chromium material for decreasing blood lipid levels and process therefor |
| US4923855A (en) | 1983-07-08 | 1990-05-08 | The William Seroy Group | Synthetic GTF chromium material and process therefor |
| US5194615A (en) | 1983-07-08 | 1993-03-16 | The William Seroy Group | Synthetic GTF chromium nicotinate material and its preparation |
| JPS62236469A (ja) | 1986-04-04 | 1987-10-16 | Yasutake Hichi | 低カロリ−飲食物 |
| US5266560A (en) * | 1988-06-03 | 1993-11-30 | Thomas Research Corporation | Pharmaceutical insulin-potentiating CR(III) complexes with GTF-like activity |
| US5543405A (en) | 1993-10-22 | 1996-08-06 | Keown; Wendy J. | Composition and method for weight reduction and long term management of obesity |
| US5480657A (en) | 1993-10-27 | 1996-01-02 | Allen; Ann De Wees T. | Composition comprising caffeine chromium and fructose for weight control and use thereof |
| US5612039A (en) | 1994-03-14 | 1997-03-18 | Nini E. Policappelli | Dietary supplement |
| US5567424A (en) | 1994-06-10 | 1996-10-22 | Reliv International, Inc. | Fiber, antioxidant, herbal and enzyme supplemented beverage composition for human consumption |
| US6352713B1 (en) | 1999-12-01 | 2002-03-05 | Drugtech Corporation | Nutritional composition |
| US5536516A (en) | 1994-08-24 | 1996-07-16 | Renaissance Herbs, Inc. | Hydroxycitric acid concentrate and food products prepared therefrom |
| US20040196181A1 (en) * | 1994-09-22 | 2004-10-07 | Huston Charles D. | Method and apparatus for message display on a golf course |
| EP0714663A3 (en) | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug responses by serotonin 1A receptor antagonists |
| AU5736096A (en) | 1995-05-15 | 1996-11-29 | Sabinsa Corporation | A new process for the production of potassium hydroxy citric acid, and compositions containing the potassium hydroxy cit ric acid |
| US5626849A (en) | 1995-06-07 | 1997-05-06 | Reliv International, Inc. | Weight loss composition for burning and reducing synthesis of fats |
| IT1276253B1 (it) | 1995-12-15 | 1997-10-27 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi |
| US5716976A (en) | 1996-03-13 | 1998-02-10 | Bernstein; Richard K. | Method of treatment for carbohydrate addiction |
| FI120290B (fi) | 1996-12-30 | 2009-09-15 | Mirador Res Oy Ltd | Menetelmä, jonka avulla voidaan valmistaa sellaisia mausteseos-, ruoan ainesosa- ja elintarvikekoostumuksia, jotka alentavat seerumin kolesterolia |
| EP1021177A4 (en) | 1997-02-04 | 2002-05-15 | John V Kosbab | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF VASCULAR DEGENERATIVE DISEASES |
| US5962030A (en) | 1997-03-07 | 1999-10-05 | Akesis Pharmaceuticals, Inc. | Dietary supplement and method of treatment for diabetic control |
| JP3736776B2 (ja) | 1997-03-25 | 2006-01-18 | 宝ホールディングス株式会社 | 新規カルシウム組成物 |
| US5981510A (en) | 1997-04-15 | 1999-11-09 | Yaizu Suisankagaku Industry Co., Ltd. | Method for treating and improving diabetes |
| US5911992A (en) | 1997-06-12 | 1999-06-15 | A. Glenn Braswell | Method for controlling weight with hypericum perforatum and garcinia cambogia |
| EP1011660A1 (en) | 1997-07-14 | 2000-06-28 | Inter-Health Nutraceuticals Incorporated | Hydroxycitric acid compositions, pharmaceutical and dietary supplements and food products made therefrom, and methods for their use in reducing body weight |
| US5877171A (en) | 1997-07-28 | 1999-03-02 | Mcleod; Malcolm N. | Method of treating pre-menstrual syndrome using chromium |
| US6160172A (en) | 1997-08-27 | 2000-12-12 | Vittal Mallya Scientific Research Foundation | Soluble double metal salt of group IA and IIA of (-) hydroxycitric acid, process of preparing the same and its use in beverages and other food products without effecting their flavor and properties |
| KR100704523B1 (ko) | 1998-02-23 | 2007-04-09 | 다이요 가가꾸 가부시끼가이샤 | 테아닌 함유 조성물 |
| US6048846A (en) | 1998-02-26 | 2000-04-11 | Cochran; Timothy M. | Compositions used in human treatment |
| US6258848B1 (en) | 1998-07-31 | 2001-07-10 | Mount Sinai Hospital | Methods and compositions for increasing insulin sensitivity |
| US5905075A (en) | 1998-08-28 | 1999-05-18 | Ambi Inc. | Chromium nicotinate compositions and uses thereof |
| WO2000012080A1 (en) | 1998-09-01 | 2000-03-09 | Amway Corporation | Diet composition and method of weight management |
| AU2851799A (en) | 1999-02-18 | 2000-09-04 | Vittal Mallya Scientific Research Foundation | Soluble double metal salt of group ia and iia of (-) hydroxycitric acid |
| WO2000057729A2 (en) | 1999-03-26 | 2000-10-05 | Akesis Pharmaceuticals, Inc. | Beverages for treatment of glucose metabolism disorders |
| US6447807B1 (en) | 1999-09-14 | 2002-09-10 | Dallas L. Clouatre | Potassium (-)-hydroxycitric acid methods for pharmaceutical preparations for stable and controlled delivery |
| US6207714B1 (en) * | 1999-09-14 | 2001-03-27 | Dallas L. Clouatre | Methods and pharmaceutical preparations for improving glucose metabolism with (−)-hydroxycitric acid |
| US20030220329A1 (en) | 1999-09-17 | 2003-11-27 | Duke University | Method of improving beta-adrenergic receptor function |
| BR0016322A (pt) | 1999-12-16 | 2002-08-27 | Mark Nutritionals Innc | Composição nutricional e métodos de produção e uso da mesma |
| US6291533B1 (en) | 1999-12-22 | 2001-09-18 | Vitamerica, Inc. | Dietary supplements for each specific blood type |
| US7015250B2 (en) | 2000-02-09 | 2006-03-21 | Glykon Technologies Group, Llc | Methods and pharmaceutical preparations for normalizing blood pressure with (-)-hydroxycitric acid |
| US6399089B1 (en) | 2000-05-15 | 2002-06-04 | A. Glenn Braswell | Compositions and methods for regulating metabolism and balancing body weight |
| US6383482B1 (en) | 2000-08-24 | 2002-05-07 | Vitacost.Com, Inc. | Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophan, glucomannan, picolinate and lactobacillus |
| JP2004509143A (ja) * | 2000-09-21 | 2004-03-25 | ニュートリション ２１、インコーポレイテッド | クロム錯体、共役脂肪酸及び／又は共役脂肪アルコールによる糖尿病の治療、体脂肪減少、インシュリン感受性の改善、高血糖症軽減及び高コレステロール血症軽減の方法及び組成物 |
| US6579866B2 (en) | 2000-12-28 | 2003-06-17 | Mccleary Larry | Composition and method for modulating nutrient partitioning |
| US6420350B1 (en) * | 2001-01-18 | 2002-07-16 | Goen Group, Inc. | Weight loss product |
| US20040157929A1 (en) | 2002-04-01 | 2004-08-12 | Ohia Sunny E. | Method for increasing serotonin levels in a person by administration of a composition incorporating(-)hydroxycitric acid, and related compositions thereof |
| MXPA03008939A (es) | 2001-03-30 | 2005-03-07 | Interhealth Nutraceuticals Inc | Metodo para incrementar los niveles de serotonina en una persona mediante la administracion de una composicion que contiene acido(-)- hidroxicitrico y composiciones relacionadas con la misma. |
| US6476071B1 (en) | 2001-05-07 | 2002-11-05 | Dallas L. Clouatre | Correcting polymorphic metabolic dysfunction with (−)-hydroxycitric acid |
| US6482858B1 (en) | 2001-06-20 | 2002-11-19 | Dallas L Clouatre | (−)-hydroxycitric acid for wound healing and immunomodulation |
| US6441041B1 (en) | 2001-06-20 | 2002-08-27 | Dallas L. Clouatre | (-)-hydroxycitric acid for the prevention of osteoporosis |
| US6638542B2 (en) | 2001-09-20 | 2003-10-28 | Nutricia N.V. | Reducing appetite in mammals by administering procyanidin and hydroxycitric acid |
| US7119110B2 (en) | 2001-10-05 | 2006-10-10 | Interhealth Nutraceuticals Incorporated | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
| US20030119913A1 (en) | 2001-12-20 | 2003-06-26 | Ohia Sunny E. | Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof |
| WO2003092730A1 (en) | 2002-04-30 | 2003-11-13 | Unibar Corporation | Hydroxycitric acid salt composition and method of making |
| US6967030B2 (en) * | 2003-01-14 | 2005-11-22 | Wright Jonathan V | Formulation for insulin and glucose control |
| TW200427447A (en) | 2003-03-21 | 2004-12-16 | Interhealth Nutraceuticals Inc | Method and composition for decreasing ghrelin levels |
-
2002
- 2002-10-04 US US10/265,093 patent/US7119110B2/en not_active Expired - Lifetime
- 2002-10-07 JP JP2003541826A patent/JP2005508371A/ja active Pending
- 2002-10-07 IL IL16118602A patent/IL161186A0/xx unknown
- 2002-10-07 WO PCT/US2002/031987 patent/WO2003039535A1/en not_active Ceased
- 2002-10-07 MX MXPA04003233A patent/MXPA04003233A/es active IP Right Grant
- 2002-10-07 CA CA002462158A patent/CA2462158A1/en not_active Abandoned
- 2002-10-07 EP EP02786372A patent/EP1438038A4/en not_active Withdrawn
- 2002-10-07 AU AU2002351456A patent/AU2002351456B2/en not_active Ceased
-
2004
- 2004-04-06 ZA ZA200402688A patent/ZA200402688B/xx unknown
- 2004-12-09 US US11/009,266 patent/US7153877B2/en not_active Expired - Lifetime
-
2005
- 2005-05-13 US US11/128,727 patent/US20050202101A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005508371A5 (enExample) | ||
| JP2005513107A5 (enExample) | ||
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| JP2004520436A5 (enExample) | ||
| JP2008524120A5 (enExample) | ||
| CA2301378A1 (en) | Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin | |
| RU2007104095A (ru) | Применение твердой пероральной дозировочной композиции пролонгированного действия для приготовления лекарственных средств | |
| Morelli et al. | Alternative therapies: Part I. Depression, diabetes, obesity | |
| JP2009518293A5 (enExample) | ||
| JP2005508963A5 (enExample) | ||
| WO2004062557A3 (de) | Pharmazeutische kombination aus telmisartan und atorvastatinph zur prophylaxe oder therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen krankheiten | |
| JP2005525329A5 (enExample) | ||
| Stals et al. | Acanthosis nigricans caused by nicotinic acid: case report and review of the literature | |
| JP2009515927A5 (enExample) | ||
| JP2011516544A5 (enExample) | ||
| AU9780598A (en) | Serotonin containing formulation for oral administration and method of use | |
| TW200427447A (en) | Method and composition for decreasing ghrelin levels | |
| WO2010044581A2 (ko) | N1-벤조[1,3]다이옥솔-5-일메틸-n2-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 함유하는 약학 조성물 | |
| WO2004062729A8 (de) | Pharmazeutische kombination zur prophylaxe oder therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen krankheiten | |
| AU2006312119B2 (en) | Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same | |
| JP2007509946A5 (enExample) | ||
| WO2006064744A1 (ja) | 糖尿病の治療のための医薬組成物 | |
| HRP20250564T1 (hr) | Pripravak furazidina s produljenim oslobađanjem | |
| JP2002348244A (ja) | 抗糖尿病組成物 | |
| CA2551043A1 (en) | The use of cystine or cysteine for the prevention and treatment of oxidative stress caused by haemodialysis and of acute or chronic kidney diseases |